Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | ACACB | O00763 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10148343 | 1.00 | ALDH1A1 (0.44) | ALDH1A1TDP1KDM4ENPC1POLB | |
| SCHEMBL10148199 | 0.90 | ALDH1A1 (0.44) | ALDH1A1TDP1KDM4ENPC1POLB | |
| SCHEMBL10148341 | 0.90 | ALDH1A1 (0.44) | ALDH1A1TDP1KDM4ENPC1POLB | |
| SCHEMBL10148311 | 0.84 | NPC1 (0.46) | ALDH1A1TDP1KDM4ENPC1POLB | |
| SCHEMBL10186101 | 0.83 | ESR1 (0.41) | ALDH1A1TDP1KDM4ENPC1POLB | |
| SCHEMBL10184970 | 0.83 | ESR1 (0.41) | ALDH1A1TDP1KDM4ENPC1POLB | |
| SCHEMBL10184960 | 0.82 | ALDH1A1 (0.39) | ALDH1A1TDP1KDM4ENPC1POLB | |
| SCHEMBL3040308 | 0.80 | NR1H2 (0.44) | ALDH1A1TDP1KDM4ESMN1; SMN2ACACB | |
| SCHEMBL2248030 | 0.80 | LGMN (0.48) | ALDH1A1TDP1KDM4ENPC1POLB | |
| SCHEMBL2243846 | 0.80 | LGMN (0.48) | ALDH1A1TDP1KDM4ENPC1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120046292-A1 | DIACYLETHYLENEDIAMINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2012-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046292-A1 | DIACYLETHYLENEDIAMINE COMPOUND | DGAT1, DGAT2, DIMT1 | ALDH1A1 963/4885TDP1 2744/4885KDM4E 3060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.